Pioneering a New Class of Vaccines for Global Unmet Medical Needs
Constantly-Mutating Global Infectious Diseases
Rapidly mutating viruses cause a threat to our healthcare systems and to our communities, as demonstrated by three coronavirus pandemics that have occurred within the past 15 years, and by the hundreds of thousands of deaths annually due to seasonal influenza epidemics. Novel vaccines are critical to protect against all current but also future strains or variants and prevent these crises in the future.
Osivax is creating a pipeline of universal vaccines to revolutionize infectious disease prevention and meet a significant medical need. These vaccine candidates are based on the oligoDOM® technology, a unique self-assembling VLP platform designed to trigger powerful T-cell and B-cell immune responses as it promotes the attachment of a nanoparticle to cells of the immune system.
Osivax is rapidly expanding its oligoDOM® based pipeline, with the following candidates currently in development: a universal influenza vaccine (OVX836) and coronavirus vaccine (OVX033), as well as a pan-strain human papillomavirus vaccine (PANHPVAX).
Multiple combination opportunities
The oligoDOM® technology platform can also be combined with other innovative vaccine technologies, like adjuvants and mRNA. Osivax is currently investigating the potential synergies of such combinations.
OVX836 – Universal Flu Vaccine Candidate
Facts about the
Influenza is a devastating disease, with routine global outbreaks that pose a profound threat to global health. Seasonal influenza kills hundreds of thousands of people annually and pandemic influenza can cause tens of millions of deaths as demonstrated by historic outbreaks.
by flu every season worldwide
emergence of a pandemic strain
within 6 months of time.
Current seasonal flu vaccines are only partially effective because they target strain-specific surface antigens, which mutate at high rates and thus change seasonally. A universal vaccine presents the highly needed opportunity to provide broa coverage across all seasonal and pandemic strains.
Osivax is creating a revolutionary universal influenza vaccine which will uniquely empower both the B-cell immune response and the T-cell immune response. Osivax will combine its best-in-class T-cell component (OVX836) with conventional flu vaccines to fully empower both arms of the immune system.
OVX836 targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, the NP is much less likely to mutate, alleviating the need for annual vaccination updates. Osivax’ oligoDOM® technology enables the transformation of the NP into a highly immunogenic antigen to trigger powerful T-cell immune responses.
Osivax’ lead candidate has shown powerful and long-lasting systemic and local immune responses in preclinical development. In vivo, it has shown strong efficacy against both A and B strain flu viruses and an excellent safety profile in a GLP toxicology study. After successful Phase 1 and Phase 2a clinical trials, OVX836 is currently being evaluated in two clinical trials:
- A dose-optimization Phase 2a clinical study conducted at the Center for Vaccinology of the Ghent University (CEVAC).
- A combination trial with a conventional flu vaccine at Nothern Beaches Clinical Centre in Sydney in Australia
OVX033 – Universal Coronavirus Vaccine Candidate
Facts about the
over the past 20 years
While currently commercialized vaccines target the constantly evolving spike surface antigens with the aim to generate B-cell responses. Osivax is creating a revolutionary universal influenza vaccine which will uniquely empower both the B-cell immune response and the T-cell immune response. Osivax will combine its best-in-class T-cell component (OVX033) with conventional COVID vaccines to fully empower both arms of the immune system.
Osivax is engineering a vaccine (OVX033) that targets the virus’ nucleocapsid, an internal and invariant antigen. This target can be transformed into a highly immunogenic antigen when enabled by the oligoDOM® technology and is expected to provide universal breadth of protection against all current and future variants of SARS-COV-2 but also against future pandemic coronaviruses.
Osivax builds on the experience gained through the development of OVX836 in influenza which helped facilitate the development and drive of OVX033 to preclinical proof-of-concept in less than one year.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 961112. This project is supported by the French State, through the Banque Publique d’Investissement (BPI) France’s programme: Programme d’investissements d’avenir